عنوان مقاله:

نویسندگان:

زهرا میرچی، زهرا میرچی

Breast cancer is a multifaceted disease, characterized by the uncontrolled growth and division of breast cells. This abnormal cell behavior can arise from various genetic, environmental, and hormonal factors, making each case unique and difficult to predict The tumor suppressor p53 was initially found in 1979 and has been recognized for its substantial association with HER2 in aggressive malignancies, especially breast cancer HER2 Is a type of tyrosine kinase receptor that plays a crucial role in promoting cell development, growth, and survival. When HER2 is overexpressed in breast cancer cells, it can lead to aggressive tumor growth and a poorer prognosis for patients. On the other hand, the tumor suppressor protein p53 is vital for cellular health in mammals. It helps protect cells from becoming cancerous due to DNA damage, maintaining genomic stability and regulating important cellular processes In some cases, mutations in P53 and overexpression of HER2 may occur together in aggressive cancers, worsening the clinical condition. The tumor microenvironment significantly affects the interactions between p53 and HER2 Combining immunotherapy with HER2-targeted drugs has become an important part of treatment for metastatic breast cancer patients. Trastuzumab and Pertuzumab are monoclonal antibodies that specifically target the extracellular dimerization domain. The combination of pertuzumab and trastuzumab, in conjunction with HER2 inhibition, constitutes a crucial component of the treatments for these patients. Several anti-HER2 antibody-drug conjugates (ADCs) have received FDA approval, including T-DM1, which decreases the risk of breast cancer recurrence by 50% compared to trastuzumab alone. Trastuzumab deruxtecan and neratinib have shown lower risks of disease progression or mortality in patients with metastatic breast cancer. Other ADCs that have been shown to be acceptable in the trials include ALT-P7, MRG002, RC-48, a166,… Eight tyrosine kinase inhibitors have been clinically confirmed, The first TKI that was approved for the treatment of breast cancer was Lapatinib, and other inhibitors, such as neratinib, afatinib, and dacomitinib, have also been approved for use in the treatment of breast cancer

P53mutation,HER2 positive,Transuzumab

برای لینک‌دهی به این مقاله از آدرس زیر استفاده نمایید:

برای ارجاع در منابع از عبارت زیر استفاده کنید:
میرچی، زهرا، میرچی، زهرا، 1404، بررسی تعاملات TP53 و HER2 در سرطان پستان: از جهش ژنتیکی تا مقاومت درمانی  ، کنگره بین المللی زیست پزشکی سرطان و سلولهای بنیادی، http://conf.sums.ac.ir/fa/archive_index.php?c=HN-icsbc1&aid=1514168